期刊文献+

2型糖尿病肾病患者血浆纤溶酶原激活物抑制剂1及核因子E2相关因子2水平变化及临床意义 被引量:2

Changes and significance of serum plasminogen activator inhibitor-1 and nuclea factor erythroid-2-related factor2 in patients of type 2 diabetic kidney disease
下载PDF
导出
摘要 目的分析在2型糖尿病肾病(DKD)患者中血浆纤溶酶原激活物抑制剂1(PAI-1)及核因子E2相关因子2(Nrf2水平的变化及意义。方法选取2019年10月~2020年12月保定市第一中心医院内分泌科收治的2型糖尿病患者167例,根据尿白蛋白/肌酐比值(UACR)分为单纯2型糖尿病组(DM组,n=58),微量蛋白尿组(DKD1组,n=59),大量蛋白尿组(DKD2组,n=50),并选取同期体检健康人群为健康对照组(NC组,n=45)。测定各组PAI-1及Nrf2水平。采用Spearman相关分析法及logistic回归分析法分析PAI-1及Nrf2与各影响因素之间的相关性及评估DKD的影响因素。采用受试者工作特征曲线(ROC)评估PAI-1及Nrf2对DKD的诊断价值。结果与NC组相比,DM组、DKD1组及DKD2组PAI-1水平依次升高,Nrf2水平依次下降,以DKD2组最显著,差异有统计学意义(P<0.05)。Spearman相关分析结果显示,PAI-1与糖尿病病程、空腹血糖、糖化血红蛋白、肌酐、UACR及24 h尿蛋白呈正相关,与白蛋白、Nrf2呈负相关(P<0.05);Nrf2与白蛋白呈正相关,与空腹血糖、糖化血红蛋白、肌酐、UACR、24 h尿蛋白及PAI-1呈负相关(P<0.05)。Logistic回归分析显示HbA1c、UACR及PAI-1为DKD的危险因素,Nrf2为DKD的保护因素。血清PAI-1及Nrf2诊断糖尿病肾病的ROC曲线下面积分别为0.818及0.802。结论糖尿病肾病患者血浆PAI-1和Nrf2与尿白蛋白有较强相关性。抑制PAI-1、提高Nrf2可能成为治疗糖尿病肾病的新靶点。 Objective To analyze the changes and the clinical values of serum PAI-1 and Nrf2 in patients of type 2 diabetic kidney disease.Methods A total of 167 patients with type 2 diabetes were selected from our hospital.According to UACR,these subjects were divided into T2DM without proteinuria group(DM group,n=58),the microalbuminuria group(DKD1 group,n=59),and the macroalbuminuria group(DKD2 group,n=50).Meanwhlie,healthy adults who underwent physical examination during the same period were selected as the control group(NC group,n=45).The clinical data of all subjects were collected,and enzyme-linked immunosorbent assay was used to determine and compare the levels of PAI-1 and Nrf2 between groups.Spearman correlation analysis was used to analyze the correlation between PAI-1 and Nrf2 and various influencing factors.Logistic regression analysis was used to to evaluate the influencing factors of DKD.The ROC curve was used to evaluate the early predictive value of PAI-1 and Nrf2 for DKD.Results Compared with NC group,the PAI-1 level increased and the Nrf2 level decreased sequentially in the DM group,the DKD1group and the DKD2 group,with the DKD2 group being the most significant(P<0.05).Spearman correlation analysis showed that PAI-1 was positively correlated with diabetes course,fasting venous blood glucose,glycosylated hemoglobin,creatinine,UACR and24h urine protein,and negatively correlated with albumin and Nrf2(P<0.05).Nrf2 was positively correlated with albumin,and negatively correlated with fasting venous blood glucose,glycosylated hemoglobin,creatinine,UACR,24h urine protein and PAI-1(P<0.05).Logistic regression analysis showed that HbA1c,UACR and PAI-1 were risk factors of DKD and Nrf2 was a protective factor of DKD.The ROC curve showed that the area under the curve of PAI-1 and Nrf2 for predicting DKD was 0.818 and 0.802,respectively,suggesting that PAI-1 and Nrf2 can help predict DKD,and PAI-1 was more sensitive than Nrf2.Conclusion Diabetes PAI-1increased and Nrf2 decreased,and the amplitude of change is strongly correlated with urinary albumin level.Inhibiting PAI-1 and raising Nrf2 level may be a new target for treating diabetes nephropathy.
作者 王翯 辛欢欢 田茜 翟娜 张浩 张云良 Wang He;Xin Huanhuan;Tian Xi(Department of Endocrinology,Baoding First Central Hospital,Baoding 071000,China)
出处 《中华保健医学杂志》 2022年第4期311-314,共4页 Chinese Journal of Health Care and Medicine
基金 保定市科学技术研究与发展指导计划(NO.17ZF187)。
关键词 血浆纤溶酶原激活物抑制剂1 核因子E2相关因子2 糖尿病 糖尿病肾病 PAI-1 Nrf2 Diabetes Mellitus Diabetic kidney disease
  • 相关文献

参考文献5

二级参考文献69

  • 1Newman DJ, Pugia M J, Lott JA, et al. Urinary protein and albumin excretion corrected by creatinine and specific gravity[ J]. Clin Chim Acta, 2000, 294(1-2) : 139-155.
  • 2National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification[ J]. Am J Kidney Dis, 2002, 39 ( 2 Suppl 1 ) : S1 -$266.
  • 3Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012,379(9818):815-822.
  • 4Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective[J]. Kidney Int, 2006,69(11):2057-2063.
  • 5Liu ZH. Nephrology in China[J]. Nat Rev Nephrol, 2013,9(9):523-528.
  • 6Woodward M, Patel A, Zoungas S, et al. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial[J]. Diabetes Care, 2011,34(12):2491-2495.
  • 7Zhuo L, Zou G, Li W, et al. Prevalence of diabetic nephropathy complicating non-diabetic renal disease among Chinese patients with type 2 diabetes mellitus[J]. Eur J Med Res, 2013,18:4.
  • 8KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease[J]. Am J Kidney Dis, 2007,49(2 Suppl 2):S12-S154.
  • 9American Diabetes Association. Standards of medical care in diabetes--2014[J]. Diabetes Care, 2014,37(Suppl 1):S14-S80.
  • 10KDOQI. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int Suppl, 2013,3(1):1-150.

共引文献474

同被引文献27

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部